Wedbush Brokers Reduce Earnings Estimates for SWTX

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Analysts at Wedbush cut their Q1 2025 EPS estimates for shares of SpringWorks Therapeutics in a research report issued on Thursday, February 20th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.84) for the quarter, down from their previous forecast of ($0.75). Wedbush has a “Outperform” rating and a $81.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($2.05) per share. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at ($0.22) EPS and FY2027 earnings at $2.90 EPS.

SWTX has been the topic of a number of other research reports. Guggenheim dropped their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday. Finally, Evercore ISI raised their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $71.50.

SpringWorks Therapeutics Stock Down 2.7 %

Shares of NASDAQ:SWTX opened at $58.29 on Monday. The business’s 50 day moving average is $41.10 and its 200 day moving average is $37.70. The stock has a market cap of $4.34 billion, a P/E ratio of -16.75 and a beta of 0.81. SpringWorks Therapeutics has a 52-week low of $28.21 and a 52-week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The company had revenue of $61.55 million for the quarter, compared to analysts’ expectations of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%.

Insider Buying and Selling

In related news, CEO Saqib Islam sold 10,672 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $59.92, for a total transaction of $639,466.24. Following the completion of the transaction, the chief executive officer now owns 1,063,953 shares in the company, valued at $63,752,063.76. The trade was a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel Lynch sold 175,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00. Following the sale, the director now directly owns 130,944 shares of the company’s stock, valued at $7,131,210.24. The trade was a 57.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 313,822 shares of company stock worth $16,802,876 in the last three months. 7.61% of the stock is owned by insiders.

Institutional Trading of SpringWorks Therapeutics

A number of institutional investors have recently made changes to their positions in SWTX. Alpha DNA Investment Management LLC acquired a new position in SpringWorks Therapeutics during the 3rd quarter valued at about $411,000. Ally Bridge Group NY LLC acquired a new position in shares of SpringWorks Therapeutics during the third quarter valued at about $7,296,000. AMI Asset Management Corp purchased a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at approximately $1,438,000. Los Angeles Capital Management LLC raised its position in shares of SpringWorks Therapeutics by 238.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock valued at $1,513,000 after purchasing an additional 33,255 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in SpringWorks Therapeutics by 20.2% in the 4th quarter. Principal Financial Group Inc. now owns 1,103,858 shares of the company’s stock worth $39,882,000 after purchasing an additional 185,413 shares in the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.